Massarweh S - Search Results

1

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. Massarweh S, et al. Breast Cancer Res Treat. 2011 Oct;129(3):819-27. doi: 10.1007/s10549-011-1679-8. Epub 2011 Jul 27. Breast Cancer Res Treat. 2011. PMID: 21792626 Free PMC article. Clinical Trial.

2

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207

3

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Massarweh S, et al. Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707. Cancer Res. 2008. PMID: 18245484

4

Pathologic changes in breast cancer after anti-estrogen therapy.

Samarnthai N, Elledge R, Prihoda TJ, Huang J, Massarweh S, Yeh IT. Samarnthai N, et al. Among authors: massarweh s. Breast J. 2012 Jul-Aug;18(4):362-6. doi: 10.1111/j.1524-4741.2012.01251.x. Epub 2012 May 23. Breast J. 2012. PMID: 22616615 Clinical Trial.

5

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, Stevens M, Elledge R. Massarweh S, et al. Breast Cancer Res Treat. 2014 Jan;143(2):325-32. doi: 10.1007/s10549-013-2810-9. Epub 2013 Dec 11. Breast Cancer Res Treat. 2014. PMID: 24327334 Clinical Trial.

6

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Creighton CJ, et al. Among authors: massarweh s. Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404. Cancer Res. 2008. PMID: 18794137 Free PMC article.

7

A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation.

Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, Pasley G, Weiss H, Massarweh S. Chen L, et al. Among authors: massarweh s. Breast Cancer Res Treat. 2012 Nov;136(2):565-72. doi: 10.1007/s10549-012-2265-4. Epub 2012 Oct 4. Breast Cancer Res Treat. 2012. PMID: 23053651

8

Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.

Massarweh S, Moss J, Wang C, Romond E, Slone S, Weiss H, Karabakhtsian RG, Napier D, Black EP. Massarweh S, et al. Future Oncol. 2014 Dec;10(15):2435-48. doi: 10.2217/fon.14.99. Future Oncol. 2014. PMID: 24826798 Free PMC article. Clinical Trial.

9

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. Chen AC, et al. Among authors: massarweh s. Breast Cancer Res Treat. 2012 Jul;134(2):583-93. doi: 10.1007/s10549-012-2082-9. Epub 2012 May 29. Breast Cancer Res Treat. 2012. PMID: 22644656 Free PMC article.

10

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Arpino G, et al. Among authors: massarweh s. J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters